Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.6 NOK | -10.83% | +2.19% | +15.23% |
Sales 2023 | 3.99M 374K | Sales 2024 * | 6.3M 590K | Capitalization | 224M 21.03M |
---|---|---|---|---|---|
Net income 2023 | -87 -8.15 | Net income 2024 * | - | EV / Sales 2023 | 48.8 x |
Net cash position 2023 * | 49.6M 4.65M | Net cash position 2024 * | 61.8M 5.79M | EV / Sales 2024 * | 25.8 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 8 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 59.06% |
Latest transcript on Lytix Biopharma
1 day | -10.83% | ||
1 week | +2.19% | ||
1 month | +1.82% | ||
3 months | -13.85% | ||
6 months | -11.81% | ||
Current year | +15.23% |
Managers | Title | Age | Since |
---|---|---|---|
Øystein Rekdal
CEO | Chief Executive Officer | - | 02-12-31 |
Gjest Breistein
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 07-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kjetil Hestdal
BRD | Director/Board Member | 64 | 21-06-06 |
Director/Board Member | 66 | 21-06-06 | |
Jayson M. Rieger
BRD | Director/Board Member | 48 | 21-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 5.6 | -10.83% | 101,936 |
24-05-15 | 6.28 | +2.95% | 14,272 |
24-05-14 | 6.1 | +5.90% | 59,634 |
24-05-13 | 5.76 | +5.11% | 5,720 |
Real-time Oslo Bors, May 16, 2024 at 10:45 am EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.23% | 21.01M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- LYTIX Stock